Business Wire

VALBIOTIS

12.6.2020 07:37:10 CEST | Business Wire | Press release

Share
VALBIOTIS Selected at the 80th Scientific Sessions of the American Diabetes Association to Present Phase II Clinical Results of TOTUM-63 in Prediabetes

VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL / PEA/SME eligible), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces that the main results of its international Phase II clinical study demonstrating the metabolic benefits of TOTUM-63 in prediabetic patients are being presented at the 80th Scientific Sessions of the American Diabetes Association (ADA).

This is the fourth time that VALBIOTIS has had its work on TOTUM-63 selected by this major congress, which is being held from 12 to 16 June this year - in virtual format, due to the COVID-19 health crisis. TOTUM-63's clinical data on carbohydrate metabolism, weight and waist circumference are presented as an e-poster (www.valbiotis.com/en/scientific-publications ). The presentation to the ADA serves as recognition by the global scientific community of the quality of the results obtained for a groundbreaking treatment to reduce the risk of developing type 2 diabetes. No clinically proven answer exists today for people with prediabetes, a reversible state of impaired glucose metabolism which, without intervention, has a 70 to 90% risk of developing into type 2 diabetes1 .

The positive results of this study were announced in two stages (press releases of 3 July 2019 and 2 September 2019 ). In order to confirm these results on a larger population and to allow healthcare professionals worldwide access to this scientific innovation, VALBIOTIS entered into a global strategic partnership with Nestlé Health Science in early 2020. This agreement covers the development and marketing of TOTUM-63 (press release of 5 February 2020 ), an innovative and patented combination of five plant extracts.

Prof. Jean-Marie Bard, Hospital Practitioner and Professor of Fundamental and Clinical Biochemistry at the University of Nantes, scientific advisor for the study comments: "The presentation of these results to the ADA marks both a real turning point in health nutrition and the recognition of the clinical efficacy of TOTUM-63. This randomized, placebo-controlled Phase II study showed a significant reduction in fasting blood glucose, its primary endpoint, as well as a significant improvement in glucose tolerance, body weight and waist circumference, secondary endpoints of the study, all known as critical risk factors for developing type 2 diabetes. The data is remarkable for its consistency and the clear metabolic impact demonstrated in 51 subjects, all with abdominal obesity associated with moderate hyperglycemia, 2-hour hyperglycemia (OGTT) and hypertriglyceridemia."

At the end of the 6-month supplementation period, fasting blood glucose levels were significantly reduced in subjects receiving 5 grams per day of TOTUM-63 compared to subjects in the control group receiving 5 grams of placebo (-0.04 ± 0.02 vs. +0.09 ± 0.04 g/L, p<0.05). TOTUM-63 also significantly reduced two-hour blood glucose, or postmeal blood glucose (-0.02 ± 0.07 vs +0.32 ± 0.17 g/L, p<0.05), body weight (-0.07 ± 0.42 vs +1.83 ± 0.57 kg; p<0.05) and waist circumference (-1.67 ± 0.73 vs +2.81 ± 0.65 cm; p<0.001).

These results place TOTUM-63 as the first clinically approved, already marketable product for prediabetic individuals (nearly 1 billion worldwide2 ) to reduce the risk of developing type 2 diabetes.

Murielle Cazaubiel, Member of the Management Board, Director of Development and Medical Affairs at Valbiotis, declares: "Participating in the ADA is part of an outstanding series of achievements for VALBIOTIS' flagship prediabetes product. In just over a year, TOTUM-63 has been successfully scaled up to industrial production and confirmed its clinical efficacy on several metabolic targets and a number of cardiovascular risk factors. It is now the subject of a global partnership with a major player in the field of health nutrition, responsible for the final phase of its development. The international Phase II/III clinical trial REVERSE-IT (press release of 2 April 2020 ) co-conducted with Nestlé Health Science will start this year with 600 participants. This trial is designed not only to confirm the positive Phase II results on fasting blood glucose levels, but also to extend evaluation of TOTUM-63 to untreated type 2 diabetics."

ABOUT VALBIOTIS

VALBIOTIS is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.
VALBIOTIS has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of nutritional health solutions designed to reduce the risk of major metabolic diseases, based on a multi-target approach and made possible by the use of plant-based ingredients.
Its products are intended to be licensed to players in the health world.
VALBIOTIS was founded in La Rochelle in early 2014 and has formed numerous partnerships with top academic centers. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63).
VALBIOTIS is a member of the “BPI Excellence” network and received “Innovative Company“ status awarded by BPI France. Valbiotis has also been awarded “Young Innovative Company” status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). VALBIOTIS is a PEA-SME eligible company.

Find out more about VALBIOTIS: www.valbiotis.com

Name: VALBIOTIS
ISIN code: FR0013254851
Mnemonic code : ALVAL

DISCLAIMER

This press release contains forward-looking statements about VALBIOTIS’ objectives, based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and uncertainties, including those described in the VALBIOTIS registration document, filed with the French Financial Markets Regulator (AMF) on 31 July 2019 (application number R19-030) as well in its supplement approved by the AMF on 9 October 2019. These documents are available on the Company’s website (www.valbiotis.com ).

This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, VALBIOTIS’ shares or securities in any country.

1 Tabak AJ. et al., Lancet, 2012
2 AEC Partners data

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Marsh’s Oliver Wyman to Acquire Financial Services and Technology Consultancy Synpulse19.11.2026 14:08:00 CET | Press release

Oliver Wyman, a global leader in management consulting and a Marsh business (NYSE:MRSH), today announced an agreement to acquire Synpulse, a global technology consulting and AI platform company serving banks, insurers, wealth managers and other financial services organizations. Terms of the deal, expected to close in early 2027, were not disclosed. Banks, insurers and asset managers face significant changes driven by advances in technology, data and AI, as well as evolving business models. As these changes accelerate, clients are looking for partners who can help them navigate every stage of transformation, from strategy to technology implementation and execution. Oliver Wyman and Synpulse have already been working together with combined teams on multiple end-to-end transformations for our clients. The acquisition will enable the two businesses to continue to work closely together, combining complementary capabilities and teams to service clients across strategy, technology and impleme

GE HealthCare’s Phase 2 Results Support Advancement of Investigational Manganese-Based MRI Contrast Agent Mangaciclanol Into Phase 3 of LUMINA Clinical Trial19.11.2026 14:00:00 CET | Press release

Key milestone in GE HealthCare’s adaptive Phase 2/3 LUMINA clinical trial, with Phase 2 results meeting primary endpoint, showing mangaciclanol and market-leading gadolinium-based agent, gadobutrol, have similar overall diagnostic preference Mangaciclanol was well tolerated in the Phase 2 stage, with no safety concerns identified following its administration Mangaciclanol has received FDA Fast Track designation, recognizing its potential to address significant unmet patient needs; approximately 65 million gadolinium-enhanced MRI procedures are performed each year GE HealthCare to present preliminary Phase 2 results at RSNA 2026 (Industry Expert Theater) GE HealthCare (Nasdaq: GEHC) today announced Phase 2 results support advancement into Phase 3 for its international, multicenter LUMINA trial of mangaciclanol, with a dose selection of 0.1mmol/kg. Mangaciclanol is an investigational manganese-based magnetic resonance imaging (MRI) contrast agent (MBCA). If approved, MBCAs could offer an

Stronghold Joins the World Economic Forum's New Champions Community19.11.2026 14:00:00 CET | Press release

Stronghold, a fintech infrastructure company, today announced that it has joined the World Economic Forum’s New Champions Community. The New Champions Community is the World Economic Forum’s global network of mission-driven companies, drawn from more than 40 countries and 20 industries. Its work centers on how businesses anticipate change, adapt to disruption and build resilience. Stronghold provides payments infrastructure for merchants and the banks that serve them. The company carries the compliance work that allows banks to serve licensed businesses they would otherwise decline, and makes that work visible to every party in a transaction. That is where resilience gets tested: whether money keeps moving when a market shifts, a rule changes or a bank revisits its risk appetite. “The New Champions Community reflects the values we care about: trust, compliance, and financial innovation,” said Tammy Camp, CEO of Stronghold. “Joining gives us the chance to learn from leaders in industrie

Ehime CATV expands public-sector connectivity in Japan with Adtran XGS-PON technology19.11.2026 14:00:00 CET | Press release

News summary: Ehime CATV needed a compact access platform to connect schools and municipal facilities without large shelf-based infrastructure Adtran’s XGS-PON technology enables the regional service provider to deliver 10Gbit/s connectivity through a scalable architecture The project creates a practical route beyond legacy EPON access networks while mitigating geopolitical supply chain risk Adtran today announced that Ehime CATV has selected its XGS-PON technology to support a new broadband network for public schools and local government offices in Ehime Prefecture, Japan. The deployment will provide 10Gbit/s connectivity to more than 100 public-sector sites, supporting digital learning, cloud-based applications and everyday online services for students, teachers and municipal users. With its compact footprint and flexible expansion model, Adtran’s access technology will help Ehime CATV transition beyond legacy EPON infrastructure to ITU-based XGS-PON. The upgrade will also support a

Update Settlement Infrastructure for New Games, Build Multi-Rail Trust Layer, and Close the Accessibility Gap in AI Economy: Ant International’s Peng Yang at SFF 202619.11.2026 13:05:00 CET | Press release

Speaking at the 2026 Singapore FinTech Festival, Ant International’s CEO Peng Yang argued that our settlement infrastructure needs to evolve beyond today’s four-party payments model to assign effectively roles and responsibilities.Ant International processed the equivalent of 1.1 trillion USD on its WhaleRTP blockchain settlement network in the last 12 months in collaboration with 23 leading global banks; expected to double in 2027.He also said that agentic economy needs to rest on a stronger multi-rail, multi-modal and multi-asset trust layer, and that good AI solutions design can power a new, more inclusive globalization project by putting the little guys on a level playing field. At the Singapore FinTech Festival, Ant International CEO Peng Yang (YP) joined Javier Pérez-Tasso of Swift and Surendra Rosha of HSBC on the panel “From Digital to Intelligent: Who Will Build the Next Financial System?”, moderated by Arjun Vir Singh of Arthur D. Little. This press release features multimedi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye